Vertex Pharmaceuticals Incorporated (VRTX) Competitors & Peers
The 5 largest companies in the same industry as Vertex Pharmaceuticals Incorporated, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| REGN | Peer | $788.04 | P/E 19.9RSI 54Cap 82.8 B |
| ARGX | Peer | $959.49 | P/E 36.2RSI 42Cap 59.4 B |
| RVMD | Peer | $204.97 | RSI 41Cap 41.4 B |
| ALNY | Peer | $255.96 | P/E 43.3RSI 51Cap 33.2 B |
| CSLLY | Peer | $31.24 | P/E 18.2RSI 61Cap 60.0 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- CRSPPartner
CRISPR + Vertex co-developed Casgevy (exa-cel) for sickle cell + beta thalassemia.
Model-inferred, unverified — treat as a lead, not evidence - RPRXSupplier
Royalty Pharma owns cystic fibrosis franchise (Trikafta) royalty from Vertex.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson is one of Vertex's primary wholesale distributors for its cystic fibrosis medicines (Trikafta/Kaftrio) in the US.
Model-inferred, unverified — treat as a lead, not evidence - ABBVCompetitor
Vertex and AbbVie compete in pain management — Vertex's Journavx (suzetrigine, Nav1.8 inhibitor) vs AbbVie's pipeline pain assets.
Model-inferred, unverified — treat as a lead, not evidence - GILDCompetitor
CF + virology overlap historically.
Model-inferred, unverified — treat as a lead, not evidence